FDA Approves BREZTRI — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's BREZTRI for COPD Treatment AstraZeneca Pharmaceuticals LP received FDA approval for BREZTRI (budesonide, glycopyrrolate, and formoterol fumarate), a once-daily triple-combination inhaler for chronic obstructive pulmonary disease, positioning the company to compete in the lucrative COPD maintenance therapy market dominated by similar combination inhalers. The approval strengthens AstraZeneca's respiratory portfolio and provides patients with an additional treatment option combining an inhaled corticosteroid, long